Cytokinetics today announced that its Phase 2 double-blind study of its experimental drug CK-274 entitled “REDWOOD-HCM” (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM (hypertrophic cardiomyopathy) has begun enrollment. The trial will enroll patients with symptomatic, obstructive HCM.
CK-274 is a next-generation cardiac myosin inhibitor which the company hopes will prove to be beneficial for the treatment of hypertrophic cardiomyopathy (HCM).
There are currently two companies in clinical trials for HCM: Cytokinetics and MyoKardia. You can read more about their efforts here and here.
HCM Beat 
Are these trials in particular countries? I’m in the UK
LikeLike
They vary. You should ask your doctor if you can participate? In the U.S. there is a database where you can look up clinical trials called clinicaltrials.gov. Not sure about what there is in the UK but you can start with clinicaltrials.gov and see where that gets you. There are some non U.S. trials posted there as well.
LikeLike